Corvus Pharmaceuticals has been granted a patent for methods and compounds that modulate Interleukin-2-inducible T-cell kinase. The patent includes a specific compound of Formula (IIA). GlobalData’s report on Corvus Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Corvus Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Corvus Pharmaceuticals's grant share as of February 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11897874B2) discloses a compound of Formula (IIA) and various derivatives with specific substituents, including hydrogen, halogen, alkyl, and heteroalkyl groups. The patent also covers pharmaceutical compositions comprising the compound and methods for treating T-cell lymphoma, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma, by administering the disclosed compound or composition to patients in need.
The patent further extends to methods of treating T-cell lymphoma using specific compounds with defined structures and pharmaceutical compositions containing these compounds. The disclosed methods aim to provide effective treatment for T-cell lymphoma, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma, with unspecified subtypes. By administering the compound or composition as described in the patent, the disclosed methods offer a targeted approach to addressing T-cell lymphoma in patients, potentially improving outcomes for individuals suffering from these conditions.
To know more about GlobalData’s detailed insights on Corvus Pharmaceuticals, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.